Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-26T12:48:03.249Z Has data issue: false hasContentIssue false
  • English
  • Français

Association Between Prolactin Gene Polymorphism (–1149 G/T) and Hyperprolactinemia in Anti-psychotic Treated Patients with Schizophrenia

Published online by Cambridge University Press:  23 March 2020

S. Ivanova ,
D. Osmanova ,
A. Boiko ,
I. Pozhidaev ,
O. Fedorenko ,
E. Kornetova ,
A. Semke ,
N. Bokhan ,
B. Wilffert  and
A. Loonen
S. Ivanova
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center of RAS, Molecular Genetics and Biochemistry Laboratory, Tomsk, Russia
D. Osmanova
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center of RAS, Molecular Genetics and Biochemistry Laboratory, Tomsk, Russia
A. Boiko
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center of RAS, Molecular Genetics and Biochemistry Laboratory, Tomsk, Russia
I. Pozhidaev
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center of RAS, Molecular Genetics and Biochemistry Laboratory, Tomsk, Russia
O. Fedorenko
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center of RAS, Molecular Genetics and Biochemistry Laboratory, Tomsk, Russia
E. Kornetova
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center of RAS, Department of Clinical Psychiatry, Tomsk, Russia
A. Semke
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center of RAS, Department of Clinical Psychiatry, Tomsk, Russia
N. Bokhan
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center of RAS, Department of Clinical Psychiatry, Tomsk, Russia
B. Wilffert
Affiliation:
University of Groningen, Department of Pharmacy, Groningen, The Netherlands
A. Loonen
Affiliation:
University of Groningen, Department of Pharmacy, Groningen, The Netherlands

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Hyperprolactinemia (HPRL) is a classical side effect of anti-psychotic drugs. Extrapituitary prolactin (PRL) production is regulated by an alternative promoter, which contains the functional single nucleotide polymorphism – 1149 G/T (rs134,1239) in prolactin gene. We examined whether this polymorphism is associated with hyperprolactinemia in patients with schizophrenia. The experimental group comprised 443 patients with schizophrenia. The control group comprised 126 healthy persons. The PRL concentration was measured in serum using the AccuBind ELISA Microwells kit. The functional polymorphism – 1149 G/T (rs134,1239) of the PRL gene was genotyped using the The MassARRAY® system. Genotype and allele frequencies were compared using χ2 test. A total of 227 patients suffered from HPRL (98 males/129 females) according to the criteria of hyperprolactinemia. The frequency of genotypes and alleles in patients with schizophrenia did not differ from those in control subjects. A comparison between patients with schizophrenia with and without hyperprolactinemia revealed that the frequency of G allele in patients with hyperprolactinemia is significantly higher than in patients without hyperprolactinemia (χ2 = 7.25; P = 0.007; OR = 1.44 [1.10–1.89]). Accordingly, the genotype GG was found to be more often in patients with hyperprolactinemia than without it (χ2 = 9.49; P = 0.009). A significant association of the polymorphic variant rs134,1239 with the development of hyperprolactinemia in patients with schizophrenia treated with anti-psychotic drugs was revealed. Therefore, the serum concentration of prolactin in anti-psychotic treatment patients with schizophrenia may also give an indication of the activity of gene regulating extrapituitary prolactin expression.

The study was supported by the Russian Science Foundation, Grant 14-35-00023.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Walk: Schizophrenia and other psychotic disorders - Part 3
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S267
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.